|
Market Cap (25-Jun) $27,342,400 (1,032nd) |
Close (30-Jun) $0.008 |
Volume (30-Jun) 285,280 |
Shortsold (12-Dec) 6,497 (0.00%) (681st) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.09 |
EX1 released this announcement to the ASX on 22 October 2020, 9:43. The announcement is not marked as price sensitive, and is 3 page(s) in length and 788.4kb in size.
You can view all announcements from EX1 and see how they appear on a price chart on the announcements page.
At the date of this announcement, EX1 was 0.011% short sold according to ASIC data. It was ranked the 588th most shorted stock on the ASX. It remains ranked 681st as of the latest reported data (12 December 2022).
| Other Recent Announcements from EX1 | |
|---|---|
| Initial Director's Interest Notice - MD | 22 June 2023, 11:52 |
| Change of Director's Interest Notice - CB | 22 June 2023, 11:51 |
| Final Director's Interest Notice - JW | 22 June 2023, 11:50 |
| Update & Changes to the Board | 22 June 2023, 11:49 |
| Change in substantial holding - ID | 18 May 2023, 11:15 |
| Application for quotation of securities - EX1 | 18 May 2023, 10:33 |
| Plexoval II First Dosing and $2.1m R&D Rebate Received | 22 October 2020, 9:43 |
| There has been no announcements made to the ASX since this one. |
You must be logged in to post a reply.
Exopharm 